PMID- 21094277
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20220309
IS  - 1549-9642 (Electronic)
IS  - 1549-9634 (Print)
IS  - 1549-9634 (Linking)
VI  - 7
IP  - 3
DP  - 2011 Jun
TI  - Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer 
      cell lines with different drug resistance mechanisms.
PG  - 324-32
LID - 10.1016/j.nano.2010.11.004 [doi]
AB  - The purpose of this study was to compare the cellular uptake and cytotoxicity of 
      targeted and nontargeted doxorubicin (DOX)-loaded poly(d,l-lactide co-glycolide) 
      (PLGA) nanoparticle (NP) drug delivery systems in drug-resistant ovarian (SKOV-3) 
      and uterine (MES-SA/Dx5) cancer cell lines. The cellular uptakes of DOX from 
      nonconjugated DOX-loaded NPs (DNPs) and from HER-2 antibody-conjugated DOX-loaded 
      NPs (ADNPs) in MES-SA/Dx5 cancer cells were higher compared to free DOX. Results 
      also showed higher uptake of DOX from ADNPs in SKOV-3 cells compared with both 
      free DOX and DNPs treatment. Cytotoxicity results at 10 muM extracellular DOX 
      concentration were consistent with the cellular uptake results. Our study 
      concludes that cellular uptake and cytotoxicity of DOX can be improved in 
      MES-SA/Dx5 cells by loading DOX into PLGA NPs. DNPs targeted to membrane 
      receptors may enhance cellular uptake and cytotoxicity in SKOV-3 cells. FROM THE 
      CLINICAL EDITOR: The authors of this study compare the cellular uptake and 
      cytotoxicity of targeted and nontargeted doxorubicin loaded PLGA nanoparticle 
      delivery systems in drug-resistant ovarian and uterine cancer cell lines, 
      concluding that cellular uptake and cytotoxicity of doxorubicin can be improved 
      by the proposed methods.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Lei, Tingjun
AU  - Lei T
AD  - Department of Biomedical Engineering, Florida International University, Miami, 
      Florida, USA.
FAU - Srinivasan, Supriya
AU  - Srinivasan S
FAU - Tang, Yuan
AU  - Tang Y
FAU - Manchanda, Romila
AU  - Manchanda R
FAU - Nagesetti, Abhignyan
AU  - Nagesetti A
FAU - Fernandez-Fernandez, Alicia
AU  - Fernandez-Fernandez A
FAU - McGoron, Anthony J
AU  - McGoron AJ
LA  - eng
GR  - R25 GM061347/GM/NIGMS NIH HHS/United States
GR  - R25 GM061347-10/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101119
PL  - United States
TA  - Nanomedicine
JT  - Nanomedicine : nanotechnology, biology, and medicine
JID - 101233142
RN  - 0 (Antibodies)
RN  - 0 (Drug Carriers)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antibodies/immunology
MH  - Biological Transport/drug effects
MH  - Cell Death/drug effects
MH  - Cell Line, Tumor
MH  - Chemistry, Pharmaceutical
MH  - Doxorubicin/pharmacology
MH  - Drug Carriers/*toxicity
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Endocytosis/*drug effects
MH  - Humans
MH  - Intracellular Space/drug effects/metabolism
MH  - Kinetics
MH  - Light
MH  - Microscopy, Confocal
MH  - Nanoparticles/chemistry
MH  - Particle Size
MH  - Scattering, Radiation
MH  - Static Electricity
MH  - Subcellular Fractions/metabolism
PMC - PMC3104086
MID - NIHMS254071
EDAT- 2010/11/26 06:00
MHDA- 2011/10/01 06:00
PMCR- 2012/06/01
CRDT- 2010/11/25 06:00
PHST- 2010/07/20 00:00 [received]
PHST- 2010/10/15 00:00 [revised]
PHST- 2010/11/08 00:00 [accepted]
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
PHST- 2012/06/01 00:00 [pmc-release]
AID - S1549-9634(10)00370-9 [pii]
AID - 10.1016/j.nano.2010.11.004 [doi]
PST - ppublish
SO  - Nanomedicine. 2011 Jun;7(3):324-32. doi: 10.1016/j.nano.2010.11.004. Epub 2010 
      Nov 19.